Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-407-6 | CAS number: 120-55-8
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
DEGDB was tested against four strains of Salmonella typhimurium and one strain of Escherichia coli, both in the presence and in the absence of metabolic activation (provided by S9 mix). Relevant positive controls were tested concurrently and provided positive results, demonstrating the sensitivity of the assay. No increases in the number of revertant colonies relative to the concurrent vehicle controls were observed for the test material in any of the strains tested. It was concluded that DEGDB showed no evidence of mutagenic activity in this bacterial system. A much earlier study (non-GLP) the test compound DEGDB was found not to demonstrate any genetic activity in this test, and was considered not mutagenic under the test conditions.
A mammalian cell mutation assay was conducted and toxicity was observed after treatment with DEGDB in all the tests both in the absence and the presence of metabolic activation (S-9 mix). No biologically significant increases in mutant frequency were observed in any of the tests either in the absence or the presence of S-9 mix. It was concluded that DEGDB did not demonstrate mutagenic potential in this in vitro mammalian cell mutation assay.
A chromosome aberration test was performed to determine the potential of DEGDB to cause chromosome aberrations in Chinese Hamster Lung (CHL) cells cultured in vitro. In both the presence and the absence of metabolic activation (S9 mix), DEGDB caused no statistically significant increase in the proportion of metaphase figures containing chromosomal aberrations at any dose level when compared with the solvent control in either of two tests. It was concluded that DEGDB had shown no evidence of clastogenic activity in this in-vitro cytogenetic test system.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
From the results of the three different in-vitro investigations, and according to the criteria laid down in Council Directive 67/548/EEC (and subsequent adaptations) the test item DEGDB, is considered as non-mutagenic and is not classified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
